Compare peptides

Compare two to four peptides side by side. Counts are exact.

Triptorelin (Trelstar, Decapeptyl)
Oxytocin

Best randomized result by outcome

For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.

Best randomized result by outcome for Triptorelin (Trelstar, Decapeptyl), Oxytocin
Outcome	Triptorelin (Trelstar, Decapeptyl)	Oxytocin
Sex hormones and fertilityEndocrine and hormonesCompared as: value in the arm that got the peptide, in %	60% Testosterone below 0.30 ng/mL · triptorelin at 1 month Dose studied: 3.75 mg monthly6 monthsn = 681997	14.4% Mean percent change testosterone Dose studied: 24 IUn = 452020

Sex hormones and fertilityEndocrine and hormonesCompared as: value in the arm that got the peptide, in %
- Triptorelin (Trelstar, Decapeptyl)
  60%
  Testosterone below 0.30 ng/mL · triptorelin at 1 month
  Dose studied: 3.75 mg monthly6 monthsn = 681997
- Oxytocin
  14.4%
  Mean percent change testosterone
  Dose studied: 24 IUn = 452020

Outcomes with a randomized result for one peptide only (11 outcomes)

The other peptides have no randomized result on the same measure, so these results cannot be set side by side.

Outcomes with a randomized result for one peptide only: Triptorelin (Trelstar, Decapeptyl), Oxytocin
Outcome	Triptorelin (Trelstar, Decapeptyl)	Oxytocin
Uterine fibroid outcomesReproductive and sexual healthCompared as: value in the arm that got the peptide, in j/mm3	No comparable result 1 randomized-trial result measure it in another way or another unit.	8.5 J/mm3 EEF Control (group D): 12.6 J/mm3 Dose studied: 0.32 IU/min

Comparing 2 peptides · Data version 308560

Only differences

Swipe sideways to see every peptide.

Comparison of Triptorelin (Trelstar, Decapeptyl), Oxytocin
Peptide	Synthetic analog Triptorelin (Trelstar, Decapeptyl)	Natural peptide Oxytocin
Identity
Kind	Synthetic analog	Natural peptide
Area	Sexual health and hormones	Sexual health and hormones
Evidence
Amount of evidence	1,338	3,492 (plus 1,148 on natural levels, listed separately)
Evidence level	Has results from studies in people	Has results from studies in people
Safety
Safety results	164 (160 in people)	157 (152 in people)
Status
Approval
Sport (WADA)
Registered trials	207 · 44 active104 more mention it but do not test it	690 · 65 active238 more mention it but do not test it

Shared outcomes

Sex hormones and fertility932
Cognition and memory418
Anxiety and mood348
Adverse events231
Receptor activity and mechanism363
Pain123
Pharmacokinetics110
Bone and joint94
Appetite and food intake95
Sexual function83
Tumor growth58
Heart function77

Approval and sport status

From the regulatory data of each peptide.

Triptorelin (Trelstar, Decapeptyl)
The FDA label for Trelstar says: “Treatment of advanced prostate cancer”
Oxytocin

Amount of evidence by outcome

Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.

Study results per shared outcome group and evidence class
Outcome group	Triptorelin (Trelstar, Decapeptyl)	Oxytocin
Sex hormones and fertilityReproductive and sexual health	78259917112

Sequence alignment

Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.

Against GonadorelinTriptorelin (Trelstar, Decapeptyl)

Triptorelin (Trelstar, Decapeptyl) differs from Gonadorelin at 2 positions and carries 1 added group.

Top row: Gonadorelin (parent)
Bottom row: Triptorelin (Trelstar, Decapeptyl)

HWSYLRP

Same as parent
Substituted
Non-canonical or D-form
Modified side chain or end

What is different

1Position 1: Xaa is replaced by Gln.
2Position 6: Gly is replaced by its mirror-image form, D-Trp.
3Position 10: Gly carries an added group: C-terminal amide.

Trials side by side

Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.

Triptorelin (Trelstar, Decapeptyl)207 registered trials

Top 3 of 207 trials, ranked by phase, then posted results and enrollment: 2 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00066690

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

ETOP IBCSG Partners Foundation3,066 participants17 Dec 2003 to 6 Nov 2024

Estrogen Receptor Positive Breast Cancer · Progesterone Receptor Positive Tumor · Recurrent Breast Carcinoma · Stage IA Breast Cancer · Stage IB Breast Cancer · Stage IIA Breast Cancer · Stage IIB Breast Cancer · Stage IIIA Breast Cancer

Trial page ClinicalTrials.gov

CompletedPhase 3Results postedNCT00066703

Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

ETOP IBCSG Partners Foundation2,672 participants3 Nov 2003 to 23 Oct 2024

Breast Cancer

Trial page ClinicalTrials.gov

Status unknownPhase 3Results postedNCT00567580

Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

Radiation Therapy Oncology Group1,792 participantsFeb 2008 to 12 Jul 2018 (primary)

Prostate Cancer

Trial page ClinicalTrials.gov

104 more mention it but do not test it. They only measure it or name it in their text.

Oxytocin690 registered trials

Top 3 of 690 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4Results postedNCT00790062

Oxytocin Regimen to Prevent Atony and Postpartum Hemorrhage During Vaginal Delivery: 3-arm RCT

University of Alabama at Birmingham1,798 participantsNov 2008 to Jun 2010

Uterine Atony · Postpartum Hemorrhage

Trial page ClinicalTrials.gov

CompletedPhase 4Results postedNCT02487797

Comparison of Low-dose and High-dose Oxytocin Regimens for Labor Augmentation

Northwestern University1,003 participants28 Sept 2015 to 28 Sept 2020

Dystocia

Trial page ClinicalTrials.gov

CompletedPhase 3Results postedNCT03463993

Efficacy of Tranexamic Acid in Preventing Postpartum Haemorrhage After Elective Caesarean Section

University of Zimbabwe506 participants8 Apr 2018 to 30 Jun 2019

Post Partum Hemorrhage

Trial page ClinicalTrials.gov

PepBank is a research reference. Talk to a doctor before you use any peptide.

Cognition and memoryNervous system and cognition	413	41440311

Anxiety and moodMental health and mood	77	34132417

Adverse eventsWhole body	105105	1261233

Receptor activity and mechanismReproductive and sexual health	7425715	28960801472

PainReproductive and sexual health	1414	1098524

PharmacokineticsPharmacology	19136	9168203

Bone and jointMusculoskeletal	74713	2020

Appetite and food intakeEndocrine and hormones	11	946727

Sexual functionReproductive and sexual health	761	7647245

Tumor growthReproductive and sexual health	524624	6411

Heart functionCardiovascular	11	76353110

Body weightMetabolic and weightCompared as: difference from placebo, in g	No comparable result 2 randomized-trial results measure it in another way or another unit.	196 g Difference in total fat Dose studied: 24 IU four times daily8 weeksn = 612024

Glycemic controlMetabolic and weightCompared as: value in the arm that got the peptide, in mmol/l × min	No comparable result 1 randomized-trial result measure it in another way or another unit.	2240 mmol/L × min Glucose AUC Placebo: 2190 mmol/L × min Dose studied: 24 IUn = 252024

LipidsCardiovascularCompared as: difference from placebo, in mg/dl	No comparable result 1 randomized-trial result measure it in another way or another unit.	−19.3 mg/dL LDL cholesterol change Dose studied: 24 IU 4 times per day8 weeksn = 212021

Growth hormone and IGF-1Endocrine and hormonesCompared as: value in the arm that got the peptide, in mu/l	No comparable result 2 randomized-trial results measure it in another way or another unit.	96 mU/l Peak plasma GH Saline: 106 mU/l n = 61988

PainNervous system and cognitionCompared as: difference from placebo, in %	No comparable result 9 randomized-trial results measure it in another way or another unit.	−11% allodynic area change Dose studied: 100 µgn = 52023

MortalityCancerCompared as: value in the arm that got the peptide, in %	97% Survival Dose studied: 3.75 mg9 monthsn = 2842003	No randomized trial result 2 results from other study designs.

Tumor growthCancerCompared as: value in the arm that got the peptide, in months	39.1 months 25th percentile BRFS Dose studied: 11.25 mg at baseline and at 3 and 6 months9 monthsn = 2262024	No randomized trial result 6 results from other study designs.

PharmacokineticsPharmacologyCompared as: value in the arm that got the peptide, in effect size	No randomized trial result 19 results from other study designs.	−1.12 effect size Effect size Dose studied: 48 IU/day6 weeksn = 1032020

Appetite and food intakeMetabolic and weightCompared as: difference from placebo, in kcal	No randomized trial result 1 result from other study designs.	−152 kcal Difference in caloric intake Dose studied: 24 IU four times daily8 weeksn = 612024

Liver fat and liver functionLiverCompared as: difference from placebo, in proportion	No randomized trial result 1 result from other study designs.	−0.01 proportion Difference in liver fat fraction Dose studied: 24 IU four times daily8 weeksn = 612024

Uterine fibroid outcomesReproductive and sexual healthCompared as: value in the arm that got the peptide, in j/mm3
- Triptorelin (Trelstar, Decapeptyl)
  No comparable result
  1 randomized-trial result measure it in another way or another unit.
- Oxytocin
  8.5 J/mm3
  EEF
  Control (group D): 12.6 J/mm3
  Dose studied: 0.32 IU/minduring ablationn = 1672021
Body weightMetabolic and weightCompared as: difference from placebo, in g
- Triptorelin (Trelstar, Decapeptyl)
  No comparable result
  2 randomized-trial results measure it in another way or another unit.
- Oxytocin
  196 g
  Difference in total fat
  Dose studied: 24 IU four times daily8 weeksn = 612024
Glycemic controlMetabolic and weightCompared as: value in the arm that got the peptide, in mmol/l × min
- Triptorelin (Trelstar, Decapeptyl)
  No comparable result
  1 randomized-trial result measure it in another way or another unit.
- Oxytocin
  2240 mmol/L × min
  Glucose AUC
  Placebo: 2190 mmol/L × min
  Dose studied: 24 IUn = 252024
LipidsCardiovascularCompared as: difference from placebo, in mg/dl
- Triptorelin (Trelstar, Decapeptyl)
  No comparable result
  1 randomized-trial result measure it in another way or another unit.
- Oxytocin
  −19.3 mg/dL
  LDL cholesterol change
  Dose studied: 24 IU 4 times per day8 weeksn = 212021
Growth hormone and IGF-1Endocrine and hormonesCompared as: value in the arm that got the peptide, in mu/l
- Triptorelin (Trelstar, Decapeptyl)
  No comparable result
  2 randomized-trial results measure it in another way or another unit.
- Oxytocin
  96 mU/l
  Peak plasma GH
  Saline: 106 mU/l
  n = 61988
PainNervous system and cognitionCompared as: difference from placebo, in %
- Triptorelin (Trelstar, Decapeptyl)
  No comparable result
  9 randomized-trial results measure it in another way or another unit.
- Oxytocin
  −11%
  allodynic area change
  Dose studied: 100 µgn = 52023
MortalityCancerCompared as: value in the arm that got the peptide, in %
- Triptorelin (Trelstar, Decapeptyl)
  97%
  Survival
  Dose studied: 3.75 mg9 monthsn = 2842003
- Oxytocin
  No randomized trial result
  2 results from other study designs.
Tumor growthCancerCompared as: value in the arm that got the peptide, in months
- Triptorelin (Trelstar, Decapeptyl)
  39.1 months
  25th percentile BRFS
  Dose studied: 11.25 mg at baseline and at 3 and 6 months9 monthsn = 2262024
- Oxytocin
  No randomized trial result
  6 results from other study designs.
PharmacokineticsPharmacologyCompared as: value in the arm that got the peptide, in effect size
- Triptorelin (Trelstar, Decapeptyl)
  No randomized trial result
  19 results from other study designs.
- Oxytocin
  −1.12 effect size
  Effect size
  Dose studied: 48 IU/day6 weeksn = 1032020
Appetite and food intakeMetabolic and weightCompared as: difference from placebo, in kcal
- Triptorelin (Trelstar, Decapeptyl)
  No randomized trial result
  1 result from other study designs.
- Oxytocin
  −152 kcal
  Difference in caloric intake
  Dose studied: 24 IU four times daily8 weeksn = 612024
Liver fat and liver functionLiverCompared as: difference from placebo, in proportion
- Triptorelin (Trelstar, Decapeptyl)
  No randomized trial result
  1 result from other study designs.
- Oxytocin
  −0.01 proportion
  Difference in liver fat fraction
  Dose studied: 24 IU four times daily8 weeksn = 612024

Trials side by side

Triptorelin (Trelstar, Decapeptyl)207 registered trials

Top 3 of 207 trials, ranked by phase, then posted results and enrollment: 2 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00066690

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

ETOP IBCSG Partners Foundation3,066 participants17 Dec 2003 to 6 Nov 2024

Trial page ClinicalTrials.gov

CompletedPhase 3Results postedNCT00066703

Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

ETOP IBCSG Partners Foundation2,672 participants3 Nov 2003 to 23 Oct 2024

Breast Cancer

Trial page ClinicalTrials.gov

Status unknownPhase 3Results postedNCT00567580

Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

Radiation Therapy Oncology Group1,792 participantsFeb 2008 to 12 Jul 2018 (primary)

Prostate Cancer

Trial page ClinicalTrials.gov

104 more mention it but do not test it. They only measure it or name it in their text.

Oxytocin690 registered trials

Top 3 of 690 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4Results postedNCT00790062

Oxytocin Regimen to Prevent Atony and Postpartum Hemorrhage During Vaginal Delivery: 3-arm RCT

University of Alabama at Birmingham1,798 participantsNov 2008 to Jun 2010

Uterine Atony · Postpartum Hemorrhage

Trial page ClinicalTrials.gov

CompletedPhase 4Results postedNCT02487797

Comparison of Low-dose and High-dose Oxytocin Regimens for Labor Augmentation

Northwestern University1,003 participants28 Sept 2015 to 28 Sept 2020

Dystocia

Trial page ClinicalTrials.gov

CompletedPhase 3Results postedNCT03463993

Efficacy of Tranexamic Acid in Preventing Postpartum Haemorrhage After Elective Caesarean Section

University of Zimbabwe506 participants8 Apr 2018 to 30 Jun 2019

Post Partum Hemorrhage

Trial page ClinicalTrials.gov